DEALS: AstraZeneca buys CAT for $1.3B

DEALS

WHO

WITH

WHAT

SCOOP

AstraZeneca

CAT

$1.3B buyout

AstraZeneca is buying out Cambridge Antibody Technology for $1.3 billion. The deal adds new antibody therapies to AZ's pipeline.

Quest Diagnostics

Focus Diagnostics

$185M buyout

Quest has agreed to buy Focus for $185M. Focus provides genetic testing along with a host of tests for infectious diseases.

Dishman Pharmaceuticals

Solutia

$74.5M buyout

India's Dishman Pharmaceuticals has inked a deal to buy Solutia's pharmaceutical services division for $74.5M.

Avanir Pharmaceuticals

Alamo Pharmaceuticals

$69M buyout

Avanir Pharmaceuticals has agreed to buy Alamo Pharmaceuticals for $29M up front and another $40M in scheduled sales milestones.

Diatos

Gilead

$4.7M licensing deal

French biotech Diatos has in-licensed the cancer drug DaunoXome from Gilead Sciences and plans to file for European approval to use the drug for acute myeloid leukemia.

Roche

Entelos

Collaboration

The companies have announced a two year collaboration in metabolic disease research. Roche will provide R&D funding and milestone payments.

Esprit Pharma

Novavax

Collaboration

Esprit Pharma has inked a deal to collaborate with Novavax on the development of a mid-stage testosterone therapy for women with sexual dysfunction.

Pharmacopeia

Cephalon

$15M development deal

Pharmacopeia has launched a drug discovery partnership with Cephalon for an up-front fee of $15M. Cephalon will identify compounds and both companies will work together to develop them.

TPG-Axon Capital

Quintiles

Development deal

Hedge fund TPG-Axon Capital has inked a deal to work with Quintiles to develop new drugs. TPG-Axon Capital will help fund drug development work through the CRO's subsidiary, NovaQuest.

China Biopharmaceuticals

RACP Pharmaceutical Holdings

Purchase

China Biopharmaceuticals has reached a deal to purchase all of the shares in RACP Pharmaceutical Holdings and its wholly owned subsidiaries, including Shenyang Enshi Pharmaceutical.